SOUTH SAN FRANCISCO, Calif. — September 18, 2025 — Leads & Copy — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) announced that Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present on Wednesday, September 24, 2025 at 9:55 AM PT at the MedInvest Biotech & Pharma Conference in Palo Alto, California. Management will also be available for one-on-one meetings with registered investors. A live webcast will be available on the company’s website.
Senti Bio is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control, designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells.
For more information, visit the conference website or the Senti Bio website. Senti Bio also uses X (@SentiBio) and LinkedIn (Senti Biosciences) to communicate with investors and the public.
Jenene Thomas, JTC Team, LLC, (908) 824-0775, SNTI@jtcir.com
Source: Senti Bio
